Gentian Diagnostics Asa · OSL:GENT
Gentian Diagnostics Asa — DNB Nordic-American Life Science Conference 2019
27 slides from Gentian Diagnostics Asa's conference presentation, Dec 5, 2019
Slide 1: Company Presentation DNB Nordic-American Life Science Conference
Company Presentation DNB Nordic-American Life Science Conference December 5, 2019
Slide 2: Important notice
Important notice This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The in
Slide 3: #DiagnosticEfficiency
#DiagnosticEfficiency www.gentia n.com
Slide 4: Gentian Diagnostics – Corporate overview
Gentian Diagnostics – Corporate overview NOK Headquartered in Moss, Norway Listed on Merkur Market since December 2016 Shares outstanding: 15.4m Market cap end 3Q NOK 723m More than 800 shareholders Major shareholders include Vatne Capital, Holta Invest, Sundrehagen family, Storebrand an
Slide 5: The in vitro diagnostics market
The in vitro diagnostics market $7B Immunochemistry target segment value Inflammatory, $80B infectious, total market value cardiac and renal diseases www.gentian.com
Slide 6: Products and Pipeline
Products and Pipeline Market size (USD) GCAL®*** 4.0B 3.0B G-1001** 2.0B Cystatin C 1.0B cCRP fCAL® fPELA®** <100M 2006 2012 2015 2018 2019 2020 2021 Year Renal Veterinary Inflammation Infection EPI* Cardiac *Exocrine Pancreatic Insufficiency ** Pipeline *** Not available in the US
Slide 7: We innovate diagnostic efficiency - based on deep patent portfolio
We innovate diagnostic efficiency - based on deep patent portfolio - Laboratory Clinical workflow outcome
Slide 8: Laboratory Workflow
Laboratory Workflow Laboratory efficiency 2.000 versus 170 tests/hr Instrument independent
Slide 9: Clinical Outcome
Clinical Outcome www.gentian.com
Slide 10: Cystatin C
Preventing severe kidney failures Cystatin C www.gentian.com
Slide 11: Kidney marker: Cystatin C
Kidney marker: Cystatin C FDA 510(k) cleared Estimated global market value of $0.5B Early detection of reduced kidney function Continued growth for the company mainly coming from China and US www.gentian.com
Slide 12: Partners Key customers and KOLs
Partners Key customers and KOLs • Beckman Coulter is one of top 3 market • Gentian is supplier or sub-supplier to many share holders in the area of clinical hospitals on the ‘America's Best Hospitals’ list **, chemistry in the US specifically in the area of kidney disease • Cystatin C of Gentian is
Slide 13: fCAL turbo
Reduces the need of colon endoscopic examination fCAL® turbo www.gentian.com
Slide 14: fCAL turbo
fCAL® turbo FDA 510(k) cleared Support diagnosis of inflammatory bowel disease (IBD) Testing of fecal samples on clinical chemistry analysers provide significantly faster results to clinicians Estimated market value of >$50M Continued growth due to increasing demand and competitive convers
Slide 15: Partners and key customers
Partners and key customers i" BUHLMANN SYNLAB \/ ra, Diagn ostics alpha laboratories 3% unitabs gentian
Slide 16: GCAL Plasma calprotectin immunoassay
Contributes to early detection of severe bacterial infections and sepsis GCAL® Plasma calprotectin immunoassay www.gentian.com * Novel biomarker in market development
Slide 17: GCAL: Novel biomarker in market development
GCAL: Novel biomarker in market development* Potential application for early detection of sepsis, other severe infections and rheumatoid arthritis Test for differentiating bacterial from viral infections Informed treatment decisions for antibiotic stewardship Reported infectious diseases mar
Slide 18: Market development timeline
Market development timeline Process has to be country specific Year 1 Clinical studies Year 2 Publications Year 3 Key Opinion Leaders support Commercial Year 4 partner contracts Early adapters Health Full commercial Year 5… take the test into routine Economical roll-out to model(s) markets/segment C
Slide 19: Study Highlights to date
Study Highlights to date Useful early marker of bacterial infections in critically ill patients, with better predictive characteristics than WBC (white blood cell count), CRP and PCT Calprotectin levels correlates with the severity of the disease Prognostic biomarker for ICU admission and mort
Slide 20: Cardiac disease marker: G-1001
Pushing the boundaries of PETIA with G-1001 in the product pipeline Cardiac disease marker: G-1001* www.gentian.com * Launch planned in 2021
Slide 21: Pipeline: G-1001
Pipeline: G-1001 Cardiac disease marker Total cardiac disease marker market value is estimated to be >$2B Launch of G-1001 is planned for 2021 Go-To-Market via OEM partner(s) Short ramp-up time, as it is established in the medical routine www.gentian.com
Slide 22: Trusted partner model
Trusted partner model Global Diagnostics Industry Distributors Companies Healthcare Providers www.gentian.com
Slide 23: Sales and revenues
Sales and revenues Revenues and Grants Consolidated (NOK) Sales revenues - geographic split MNOK 3Q19 3Q18 9M19 9M18 US 0.3 0.3 1.4 1.3 20 000 000 18 000 000 Europe 7.7 6.0 22.8 19.6 16 000 000 14 000 000 Asia 5.0 4.1 9.6 7.9 12 000 000 Total 13.1 10.4 33.9 28.8 10 000 000 8 000 000 6 000 000 Sales
Slide 24: Financial key figures per 3Q 2019
Financial key figures per 3Q 2019 MNOK 2019 2018 Diff % Sales 33.9 28.8 5.1 17.7 Other Revenues 5.0 11.7 - 6.7 - 57.3 Total Revenues 38.9 40.6 - 1.7 - 4.2 COGS 7.5 6.5 1.0 15.4 Production Costs 11.3 10.1 1.2 11.9 R&D Costs 14.7 14.2 0.5 3.5 SG&A 22.1 17.3 4.8 27.7 Capitalization -1.9 -3.1 1.2 38.7 O
Slide 25: Cash flow and cash position
Cash flow and cash position MNOK 3Q19 9M19 9M18 Operating activities -8.1 - 25.7 - 17.0 Investing activities - 1.5 - 3.3 - 3.9 Other changes in financial items 0.0 0.0 0.0 Financing activities 0.5 0.5 68.8 Changes in cash and cash equivalent -9.1 -28.5 47.9 Cash and cash equivalent at the beginning
Slide 26: Summary
Summary Technology innovator with global footprint Customers benefit from product solutions for diagnostic efficiency Double digit sales growth Targeted investments to secure future ambitions Current business plan is fully funded www.gentian.com
Slide 27: Get in touch with us
Get in touch with us www.gentian.com – info@gentian.com HQ GENTIAN AS Bjørnåsveien 5, 1596 Moss, Norway GENTIAN DIAGNOSTICS AB Kungsgatan 8111 43 Stockholm, Sweden GENTIAN USA INC. 215 N Eola Dr, Orlando, Florida US BEIJING REP. OFFICE Chaoyangmen Outer St Jia No.10 Chaoyang District, Beijing, China
Gentian Diagnostics — DNB Nordic-American Life Science Conference 2019 on 6ix